Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA trial

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1954-1960

  Metzger Filho, Otto ^a,b   Procter, Marion ^c   De Azambuja, Evandro ^b   Leyland Jones, Brian ^g   Gelber, Richard D ⁱ   Dowsett, Mitchell ^d   Loi, Sherene ^h   Saini, Kamal S ^b   Cameron, David ^f   Untch, Michael ^j   Smith, Ian ^d,e   Gianni, Luca ^l   Baselga, Jose ⁿ   Jackisch, Christian ^k   Bell, Richard ^a   Sotiriou, Christos ^b   Viale, Giuseppe ^m   Piccart Gebhart, Martine ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^d Royal Marsden Hospital   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g Edith Sanford Breast Cancer Research   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ Andrew Love Cancer Centre   (Australia)

^j Helios Klinikum   (Germany)

^k Klinikum Offenbach   (Germany)

^l San Raffaele Institute   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE DOSAGE; HAZARD RATIO; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; LOBULAR CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR INVASION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880681360     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2440     Document Type: Article

References (27)

1. Arpino G, Bardou VJ, Clark GM, et al: Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res 6:R149-R156, 2004
2. Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study. J Surg Oncol 48:28-33, 1991
3. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48, 2005
4. Rakha EA, Ellis IO: Lobular breast carcinoma and its variants. Semin Diagn Pathol 27:49-61, 2010
5. Sastre-Garau X, Jouve M, Asselain B, et al: Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113-120, 1996
6. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-protein overexpression in breast cancer: Association with comedo-Type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
7. Barnes DM, Lammie GA, Millis RR, et al: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58:448-452, 1988
8. Marx D, Schauer A, Reiche C, et al: C-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116:15-20, 1990
9. Ro JS, el-Naggar A, Ro JY, et al: C-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989
10. Mahtani RL, Vogel CL: Pleomorphic lobular carcinoma of the breast: Four long-Term responders to trastuzumab-Coincidence or hint? J Clin Oncol 26:5823-5824, 2008
11. Soomro S, Shousha S, Taylor P, et al: C-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 44:211-214, 1991
12. Iorfida M, Maiorano E, Orvieto E, et al: Invasive lobular breast cancer: Subtypes and outcome. Breast Cancer Res Treat 133:713-723, 2012
13. Yu J, Dabbs DJ, Shuai Y, et al: Classical-Type invasive lobular carcinoma with HER2 overexpression. Am J Clin Pathol 136:88-97, 2011
14. Hoff ER, Tubbs RR, Myles JL, et al: HER2/neu amplification in breast cancer: Stratification by tumor type and grade. Am J Clin Pathol 117:916-921, 2002
15. Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3, 655 invasive breast carcinomas. Am J Clin Pathol 123:541-546, 2005
16. Porter PL, Garcia R, Moe R, et al: C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68:331-334, 1991
17. Middleton LP, Palacios DM, Bryant BR, et al: Pleomorphic lobular carcinoma: Morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24:1650-1656, 2000
18. Metzger-Filho O, Singhal SK, Michiels S, et al: Invasive lobular carcinoma: A luminal breast cancer histotype enriched for epithelial-To-mesenchymal transition features. Cancer Res 71:24s, 2011 (suppl; abstr P2-18-01)
19. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
21. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
22. Saini KS, Azim HA Jr, Metzger-Filho O, et al: Beyond trastuzumab: New treatment options for HER2-positive breast cancer. Breast 20:S20-S27, 2011 (suppl 3)
23. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
24. Dowsett M, Procter M, McCaskill-Stevens W, et al: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27:2962-2969, 2009
25. Metzger-Filho O, Michiels S, Bertucci F, et al: Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol 24:377-384, 2013
26. Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat Rev Clin Oncol 6:718-730, 2009
27. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptorpositive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003